Join the Giant Cell Arteritis group to help and get support from people like you.
Giant Cell Arteritis News
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), 15 mg, once daily, for the t...
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
JERSEY CITY, N.J., Jan. 30, 2025 – Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...
FDA Approves Tyenne (tocilizumab-aazg), a Biosimilar to Actemra
March 7, 2024 – Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...
FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis
May 22, 2017 – The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the...